Drug profile · INN
elexacaftor, ivacaftor, tezacaftor
TRIKAFTA (COPACKAGED)
elexacaftor, ivacaftor, tezacaftor (TRIKAFTA (COPACKAGED)) is an FDA-listed pharmaceutical active ingredient. Associated with Vertex Pharmaceuticals (Australia) Pty.. Route of administration: oral. Current US regulatory status: approved.
Drug details — elexacaftor, ivacaftor, tezacaftor
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 20
- Programs
- 1
- Data quality
- 0.89
Quick answer
elexacaftor, ivacaftor, tezacaftor (TRIKAFTA (COPACKAGED)) is an FDA-listed pharmaceutical active ingredient. Associated with Vertex Pharmaceuticals (Australia) Pty.. Route of administration: oral. Current US regulatory status: approved.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related patents
-
US 12421251
Cystic fibrosis transmembrane conductance regulator modulating agents
granted -
US 12384790
Pteridinone compounds and uses thereof
granted -
US 12377252
Implantation devices, system, and methods
granted -
US 12350262
Methods of treatment for cystic fibrosis
granted -
US 12324802
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 12281057
Carboxamides as modulators of sodium channels
granted -
US 12269831
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 12258333
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
granted -
US 12247021
Substituted tetrahydrofurans as modulators of sodium channels
granted -
US 12214083
Pharmaceutical composition and administrations thereof
granted -
US 12194138
Devices and methods for delivering therapeutics
granted -
US 12168009
Modulators of cystic fibrosis transmembrane conductance regulator
granted -
US 12031150
Methods, compositions and kits for increasing genome editing efficiency
granted -
US 11951206
Cell housing device
granted -
US 11951212
Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
granted -
US 11919887
Substituted tetrahydrofurans as modulators of sodium channels
granted -
US 11827627
N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
granted -
US 11773119
Prodrugs of pyridone amides useful as modulators of sodium channels
granted -
US 11752106
Pharmaceutical composition and administrations thereof
granted -
US 11673864
Pyridone amides as modulators of sodium channels
granted
Frequently asked questions
What is elexacaftor, ivacaftor, tezacaftor?
elexacaftor, ivacaftor, tezacaftor (TRIKAFTA (COPACKAGED)) is an FDA-listed pharmaceutical active ingredient. Associated with Vertex Pharmaceuticals (Australia) Pty.. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for elexacaftor, ivacaftor, tezacaftor?
TRIKAFTA (COPACKAGED) is a marketed brand name for elexacaftor, ivacaftor, tezacaftor. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of elexacaftor, ivacaftor, tezacaftor?
elexacaftor, ivacaftor, tezacaftor has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.